COST-CONSEQUENCES ANALYSIS OF COFORMULATED ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE IN PATIENT POPULATIONS WITH DIFFERING RISK PROFILES

May 1, 2016, 00:00
10.1016/j.jval.2016.03.1206
https://www.valueinhealthjournal.com/article/S1098-3015(16)01274-2/fulltext
Title : COST-CONSEQUENCES ANALYSIS OF COFORMULATED ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE IN PATIENT POPULATIONS WITH DIFFERING RISK PROFILES
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)01274-2&doi=10.1016/j.jval.2016.03.1206
First page : A214
Section Title : Infection - Cost Studies
Open access? : No
Section Order : 707
Categories :
Tags :
Regions :
ViH Article Tags :